Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib in SMO or PTCH1 Mutated Tumors (MATCH Subprotocol T)
NCT06357988Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2016
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vismodegib in solid tumor, lymphoma, multiple myeloma (MM), sponsored by National Cancer Institute. Started Jun 2016; status: active, not recruiting.
02
Drugs
vismodegib
03
Conditions
solid tumorlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06357988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06357988.